Patents by Inventor Ning-Sheng Liang

Ning-Sheng Liang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Recombinant antibacterial group IIA phospholipase A2 and methods of use thereof
    Patent number: 6767538
    Abstract: Disclose herein is a novel recombinant mutant protein of human Group IIA phospholipase A2 (PLA2) which has enhanced antibacterial activity when compared to the wild-type human Group IIA PLA2, pharmaceutical formulations comprising the protein and methods of use thereof. Additionally, the formulations may comprise other bioactive compounds, such as, e.g., conventional antibiotics, that act additively or synergistically with Group IIA PLA2 in order to promote bacterial killing.
    Type: Grant
    Filed: September 25, 2002
    Date of Patent: July 27, 2004
    Assignee: New York University
    Inventors: Jerrold Weiss, Peter Elsbach, Ning-Sheng Liang
  • Recombinant antibacterial group IIA phospholipase A2 and methods of use thereof
    Publication number: 20030161822
    Abstract: Disclose herein is a novel recombinant mutant protein of human Group IIA phospholipase A2 (PLA2) which has enhanced antibacterial activity when compared to the wild-type human Group IIA PLA2, pharmaceutical formulations comprising the protein and methods of use thereof. Additionally, the formulations may comprise other bioactive compounds, such as, e.g., conventional antibiotics, that act additively or synergistically with Group IIA PLA2 in order to promote bacterial killing.
    Type: Application
    Filed: September 25, 2002
    Publication date: August 28, 2003
    Applicant: New York University
    Inventors: Jerrold Weiss, Peter Elsbach, Ning-Sheng Liang
  • RECOMBINANT ANTIBACTERIAL GROUP IIA PHOSPHOLIPASE A2 AND METHODS OF USE THEREOF
    Publication number: 20020172668
    Abstract: Disclose herein is a novel recombinant mutant protein of human Group IIA phospholipase A2 (PLA2) which has enhanced antibacterial activity when compared to the wild-type human Group IIA PLA2, pharmaceutical formulations comprising the protein and methods of use thereof. Additionally, the formulations may comprise other bioactive compounds, such as, e.g., conventional antibiotics, that act additively or synergistically with Group IIA PLA2 in order to promote bacterial killing.
    Type: Application
    Filed: December 18, 2000
    Publication date: November 21, 2002
    Applicant: New York University
    Inventors: Jerrold Weiss, Peter Elsbach, Ning Sheng Liang
  • Recombinant antibacterial group IIA phospholipase A2 and methods of use thereof
    Patent number: 6475484
    Abstract: Disclose herein is a novel recombinant mutant protein of human Group IIA phospholipase A (PLA2) which has enhanced antibacterial activity when compared to the wild-type human Group IIA PLA2, pharmaceutical formulations comprising the protein and methods of use thereof. Additionally, the formulations may comprise other bioactive compounds, such as, e.g., conventional antibiotics, that act additively or synergistically with Group IIA PLA2 in order to promote bacterial killing.
    Type: Grant
    Filed: December 18, 2000
    Date of Patent: November 5, 2002
    Assignee: New York University
    Inventors: Jerrold Weiss, Peter Elsbach, Ning-Sheng Liang